All In Biotech

Drug Trial Radar · NCT06164587

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

A Non-Randomized, Open Label, Safety and Efficacy Study Evaluating Kamuvudine-8 (K8) for the Treatment of Patients With Geographic Atrophy

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Apr 18, 2024

Primary completion

May 15, 2026

Study completion May 15, 2026

Sponsor

Lead sponsor
Inflammasome TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Number of participants has been expanded to 30. Participants will have 7 scheduled visits - Screening with baseline (injection), safety visit 2 days after injection, week 4, week 13 (injection), safety visit 2 days after injection, week 17, week 26. Exams will look for continuous changes in visual acuity, change in area of geographic atrophy lesions in diagnostic imaging, response measured by multifocal electroretinogram, change in reading speed, and change in microperimetry response.

Conditions

  • Geographic Atrophy
  • Age-Related Macular Degeneration

Interventions

  • K8Drug

    sustained released bio-erodible intravitreal implants

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Within the study period (of 26 weeks)
  2. Mean change in best-corrected visual acuity (BCVA)Time frame: At baseline visit, week 13 visit, and week 26 visit
  3. Mean change in low-luminance best-corrected visual acuity (ll-BCVA)Time frame: At baseline visit, week 13 visit, and week 26 visit
  4. Change in size of geographic atrophy (GA) on fundus autofluorescence (FAF)Time frame: At baseline visit, week 13 visit, and week 26 visit
  5. change in size of geographic atrophy (GA) on optical coherence tomography (OCT)Time frame: At baseline visit, week 13 visit, and week 26 visit
  6. change in size of geographic atrophy (GA) on fluorescein angiogram (FA)Time frame: At baseline visit, week 13 visit, and week 26 visit
  7. Change in multifocal electroretinograms (mfERG) responseTime frame: At baseline visit, week 13 visit, and week 26 visit
  8. Change in microperimetry responseTime frame: At baseline visit, week 13 visit, and week 26 visit
  9. Change in reading speedTime frame: At baseline visit, week 13 visit, and week 26 visit
  10. Discontinued subjectsTime frame: This will be done at every scheduled visit and any unscheduled visit, as well as when reported by participants (for 26 weeks)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University

    Loma Linda, California

  • University of Kentucky Advanced Eye Care

    Lexington, Kentucky

  • The Maine Eye Center

    Portland, Maine

  • Oregon Eye Consultants, Cascade Medical Research

    Eugene, Oregon

  • Hilton Head Retina Institute

    Hilton Head, South Carolina

  • Ophthalmology LTD

    Sioux Falls, South Dakota

  • Southeastern Retina Associates

    Hixson, Tennessee

  • Southeastern Retina Associates

    Bristol, Virginia

  • Vistar Eye Center

    Roanoke, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.